L Kyne

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Toxin A-negative, toxin B-positive Clostridium difficile
    Denise Drudy
    Centre for Food Safety, School of Agriculture, Food Science and Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland
    Int J Infect Dis 11:5-10. 2007
  2. ncbi request reprint Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea
    L Kyne
    Gerontology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Lancet 357:189-93. 2001
  3. ncbi request reprint Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile
    Lorraine Kyne
    Division of Gerontology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, 02215, USA
    Clin Infect Dis 34:346-53. 2002
  4. ncbi request reprint Clostridium difficile
    L Kyne
    Harvard Medical School, Gerontology Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Gastroenterol Clin North Am 30:753-77, ix-x. 2001
  5. ncbi request reprint Factors associated with prolonged symptoms and severe disease due to Clostridium difficile
    L Kyne
    Beth Israel Deaconess Medical Center, Gerontology Division, Boston, MA 02115, USA
    Age Ageing 28:107-13. 1999
  6. ncbi request reprint Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile
    Denise Drudy
    Centre for Food Safety, School of Agriculture, University College, Dublin, Ireland
    Infect Control Hosp Epidemiol 28:932-40. 2007
  7. ncbi request reprint Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea
    Stavros Sougioultzis
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, 02215, USA
    Gastroenterology 128:764-70. 2005
  8. ncbi request reprint Human antibody response to surface layer proteins in Clostridium difficile infection
    Denise Drudy
    Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    FEMS Immunol Med Microbiol 41:237-42. 2004
  9. ncbi request reprint Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea
    Lorraine Kyne
    Gerontology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Infect Control Hosp Epidemiol 23:653-9. 2002
  10. pmc Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A
    Samer Aboudola
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Infect Immun 71:1608-10. 2003

Research Grants

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Toxin A-negative, toxin B-positive Clostridium difficile
    Denise Drudy
    Centre for Food Safety, School of Agriculture, Food Science and Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland
    Int J Infect Dis 11:5-10. 2007
    ..This perspective describes these important toxin variant strains and highlights the need to use Clostridium difficile diagnostic methods that can detect both TcdA and TcdB...
  2. ncbi request reprint Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea
    L Kyne
    Gerontology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Lancet 357:189-93. 2001
    ..The aim of this study was to determine whether an acquired immune response to toxin A, during an episode of C. difficile diarrhoea, influences risk of recurrence...
  3. ncbi request reprint Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile
    Lorraine Kyne
    Division of Gerontology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, 02215, USA
    Clin Infect Dis 34:346-53. 2002
    ..On the basis of the findings of this study, a conservative estimate of the cost of this disease in the United States exceeds $1.1 billion per year...
  4. ncbi request reprint Clostridium difficile
    L Kyne
    Harvard Medical School, Gerontology Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Gastroenterol Clin North Am 30:753-77, ix-x. 2001
    ..Ultimately, active or passive immunization against C. difficile may be an effective means of controlling the growing problem of nosocomial C. difficile diarrhea and colitis...
  5. ncbi request reprint Factors associated with prolonged symptoms and severe disease due to Clostridium difficile
    L Kyne
    Beth Israel Deaconess Medical Center, Gerontology Division, Boston, MA 02115, USA
    Age Ageing 28:107-13. 1999
    ..This study attempts to determine the proportion of patients in each category of severity and evaluate the risk factors for a more prolonged and complicated course...
  6. ncbi request reprint Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile
    Denise Drudy
    Centre for Food Safety, School of Agriculture, University College, Dublin, Ireland
    Infect Control Hosp Epidemiol 28:932-40. 2007
    ..Between August 2003 and January 2004, we experienced an increase in the incidence of C. difficile-associated disease. We describe the investigation into and management of the outbreak in this article...
  7. ncbi request reprint Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea
    Stavros Sougioultzis
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, 02215, USA
    Gastroenterology 128:764-70. 2005
    ..Our aim was to examine whether the vaccine is also well tolerated and immunogenic in patients with recurrent CDAD...
  8. ncbi request reprint Human antibody response to surface layer proteins in Clostridium difficile infection
    Denise Drudy
    Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    FEMS Immunol Med Microbiol 41:237-42. 2004
    ..6-376.3). Further studies which examine the specific anti-SLP antibody responses to the colonising strain are warranted to determine if immune responses to C. difficile SLPs play a role in protection from CDAD...
  9. ncbi request reprint Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea
    Lorraine Kyne
    Gerontology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Infect Control Hosp Epidemiol 23:653-9. 2002
    ..To determine the diagnostic accuracy of an index of underlying disease severity (Horn's index) in identifying patients with a high probability of having nosocomial Clostridium difficile diarrhea as a complication of antimicrobial therapy...
  10. pmc Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A
    Samer Aboudola
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Infect Immun 71:1608-10. 2003
    ..These findings support the feasibility of using a vaccine to protect high-risk individuals against C. difficile-associated diarrhea and colitis...
  11. ncbi request reprint High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile
    Denise Drudy
    Centre for Food Safety, School of Agriculture, Food Science and Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland
    J Antimicrob Chemother 58:1264-7. 2006
    ..To determine the mechanism of high-level resistance to fluoroquinolone antimicrobials in toxin-A-negative, toxin-B-positive (A- B+) Clostridium difficile isolates...
  12. pmc gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027
    Denise Drudy
    Emerg Infect Dis 13:504-5. 2007
  13. doi request reprint Immunoreactive cell wall proteins of Clostridium difficile identified by human sera
    Anne Wright
    1Centre for Molecular Microbiology and Infection, Division of Cell and Molecular Biology, Imperial College, London SW7 2AZ, UK
    J Med Microbiol 57:750-6. 2008
    ..The role of these proteins as potential vaccine candidates and their roles in pathogenesis deserve further study...

Research Grants1

  1. AGING AND THE HUMAN ANTIBODY RESPONSE TO C. DIFFICILE
    Lorraine Kyne; Fiscal Year: 2004
    ..abstract_text> ..